Edition:
United States

Jazz Pharmaceuticals PLC (JAZZ.OQ)

JAZZ.OQ on NASDAQ Stock Exchange Global Select Market

151.11USD
26 May 2017
Change (% chg)

$-0.94 (-0.62%)
Prev Close
$152.05
Open
$152.88
Day's High
$153.31
Day's Low
$150.98
Volume
101,093
Avg. Vol
173,091
52-wk High
$163.69
52-wk Low
$95.80

Select another date:

Wed, May 24 2017

BRIEF-Jazz Pharma to present key data on sleeping disorder drug at meeting

* Jazz pharmaceuticals to present phase 3 data on jzp-110, an investigational treatment for excessive sleepiness in patients with narcolepsy and with obstructive sleep apnea, during 31st annual sleep meeting Source text for Eikon: Further company coverage:

BRIEF-Jazz pharmaceuticals announces Q1 2017 financial results

* Jazz pharmaceuticals announces first quarter 2017 financial results

BRIEF-Jazz Pharmaceuticals announces positive results of JZP-110 study

* Jazz Pharmaceuticals announces positive results from the phase 3 tones 2 study of jzp-110 in narcolepsy patients with excessive sleepiness

BRIEF-Jazz Pharmaceuticals reports psoitive data from phase 2/3 study of Xyrem

* Jazz Pharmaceuticals announces positive results from the phase 2/3 express study of xyrem in pediatric patients with narcolepsy with cataplexy

RPT-BRIEF-Hikma enters into settlement agreement with Jazz

* Enters into settlement agreement with Jazz for sodium oxybate

BRIEF-Hikma enters into settlement agreement with Jazz

* Enters into settlement agreement with Jazz for sodium oxybate

BRIEF-Jazz Pharma settles Xyrem patent litigation with Hikma Pharma

* Jazz Pharmaceuticals reaches settlement with Hikma Pharmaceuticals related to Xyrem patent litigation

BRIEF-Jazz Pharma says completes rolling submission of NDA for Vyxeos (CPX-351)

* Jazz pharmaceuticals completes rolling submission of new drug application for vyxeos™ (cpx-351), an investigational treatment for acute myeloid leukemia

BRIEF-Jazz pharmaceuticals and Nippon Shinyaku enter into license agreements for development and commercialization of Defitelio and Vyxeos in Japan

* Jazz Pharmaceuticals Plc - co and Nippon Shinyaku enter into license agreements for development and commercialization of Defitelio and Vyxeos in Japan

BRIEF-Jazz Pharmaceuticals announces positive results from phase 3 tones 3 and tones 4 studies of JZP-110

* Jazz pharmaceuticals announces positive results from the phase 3 tones 3 and tones 4 studies of jzp-110 in patients with obstructive sleep apnea Source text for Eikon: Further company coverage:

Select another date:

More From Around the Web